Kesimpta vs Ocrevus: Which Is the Better Option for Multiple Sclerosis Treatment?

 Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system, disrupting communication between the brain and body. For patients living with MS, finding an effective and manageable treatment is crucial. Two commonly prescribed therapies—Kesimpta (ofatumumab) and Ocrevus (ocrelizumab)—are both disease-modifying therapies (DMTs) that aim to reduce the frequency of relapses and slow disease progression. But how do they compare? What is Kesimpta? Kesimpta is a targeted B-cell therapy approved by the FDA in 2020 for adults with relapsing forms of MS. It works by depleting specific B cells that are believed to contribute to the progression of MS. Kesimpta is unique in that it is self-administered via subcutaneous injection once a month, offering patients more flexibility and convenience. What is Ocrevus? Ocrevus, approved in 2017, is another B-cell depleting therapy indicated for both relapsing and primary progressive forms of MS. Unlike Kesimpta, O...